PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2018; 118(08): 1397-1408
DOI: 10.1055/s-0038-1661393
Cellular Haemostasis and Platelets
Georg Thieme Verlag KG Stuttgart · New York

Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation

Eszter Palyu   *
1   Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
,
Jolan Harsfalvi   *
2   Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
,
Tamas Tornai
1   Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
,
Maria Papp
1   Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
,
Miklos Udvardy
3   Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
,
Katalin Szekeres-Csiki
3   Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
,
Lajos Pataki
3   Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
,
Karen Vanhoorelbeke
4   Laboratory for Thrombosis Research, IRF Life Science, KU Leuven Kulak, Kortrijk, Belgium
,
Hendrik B. Feys
5   Transfusion Research Center, Belgian Red Cross-Flanders, Ghent, Belgium
6   Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium
,
Hans Deckmyn
4   Laboratory for Thrombosis Research, IRF Life Science, KU Leuven Kulak, Kortrijk, Belgium
,
Istvan Tornai
1   Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
› Institutsangaben Funding This work was supported by a research grant of the National Research Development and Innovation Office (NVKP-16-1-2016-0017).
Weitere Informationen

Publikationsverlauf

21. März 2018

17. Mai 2018

Publikationsdatum:
04. Juli 2018 (online)

   Lizenzen und Reprints

Abstract

Background There is an unstable balance between pro- and anti-haemostatic processes in patients with cirrhosis. We hypothesized, that in patients with acute decompensation (AD) the major alterations of von Willebrand factor (VWF) could contribute to the pro-thrombotic situation as compared to patients with stable (ST) cirrhosis.

Patients and Methods We analysed different parameters of VWF, including detailed multimer distribution by densitometry and platelet adhesion, together with a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) activity and antigen and C-reactive protein (CRP) levels in patients with ST cirrhosis (n = 99), with AD (n = 54) and controls (n = 92).

Results VWF antigen, ristocetin co-factor as well as collagen-binding activities were elevated in both cirrhotic groups in a stepwise manner. There was a decrease in high and an increase in low molecular weight multimer ratios in the majority of ST cirrhosis. However, in 24 out of 54 AD patients, ultra-large VWF multimers (ultra-large molecular weight multimers [ULMWM]) were found. ADAMTS13 activity in ST and AD patients without ULMWM was similar to controls (median [interquartile range; IQR]%: 98 [67–132] and 91 [60–110] vs. 106 [88–117], respectively). The presence of ULMWM in AD patients was associated with low ADAMTS13 activity [33 (24–49)%] and high CRP level [23 (7.1–83.6) mg/L]. Adhesion of normal platelets showed a stepwise increase in the presence of cirrhotic plasmas, reaching the highest level in AD patients with ULMWM.

Conclusion Characteristic changes of VWF parameters are seen in ST cirrhosis. In AD patients, highly increased VWF and reduced ADAMTS13 activity could be found, along with the presence of ULMWM, which are possible markers and contributors of the disease progression.

Keywords

cirrhosis - acute decompensation - systemic inflammation - von Willebrand factor multimers - thrombotic micro-angiopathy

Supplementary Material

 

  • References

  • 1 Tripodi A. Liver disease and hemostatic (dys)function. Semin Thromb Hemost 2015; 41 (05) 462-467
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116 (06) 878-885
    CrossrefPubMedGoogle Scholar
  • 3 Lisman T, Bongers TN, Adelmeijer J. , et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44 (01) 53-61
    CrossrefPubMedGoogle Scholar
  • 4 Wannhoff A, Müller OJ, Friedrich K. , et al. Effects of increased von Willebrand factor levels on primary hemostasis in thrombocytopenic patients with liver cirrhosis. PLoS One 2014; 9 (11) e112583
    CrossrefPubMedGoogle Scholar
  • 5 La Mura V, Reverter JC, Flores-Arroyo A. , et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut 2011; 60 (08) 1133-1138
    CrossrefPubMedGoogle Scholar
  • 6 Ferlitsch M, Reiberger T, Hoke M. , et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology 2012; 56 (04) 1439-1447
    CrossrefPubMedGoogle Scholar
  • 7 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98 (06) 1662-1666
    CrossrefPubMedGoogle Scholar
  • 8 Sadler JE. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. Blood 2008; 112 (01) 11-18
    CrossrefPubMedGoogle Scholar
  • 9 Zhou W, Inada M, Lee TP. , et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest 2005; 85 (06) 780-788
    CrossrefPubMedGoogle Scholar
  • 10 Uemura M, Tatsumi K, Matsumoto M. , et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 2005; 106 (03) 922-924
    CrossrefPubMedGoogle Scholar
  • 11 Atzori L, Poli G, Perra A. Hepatic stellate cell: a star cell in the liver. Int J Biochem Cell Biol 2009; 41 (8-9): 1639-1642
    CrossrefPubMedGoogle Scholar
  • 12 Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (09) 2730-2735
    CrossrefPubMedGoogle Scholar
  • 13 Feys HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2007; 138 (04) 534-540
    CrossrefPubMedGoogle Scholar
  • 14 Anstee QM, Dhar A, Thursz MR. The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 2011; 35 (8-9): 526-533
    CrossrefPubMedGoogle Scholar
  • 15 Papp M, Vitalis Z, Altorjay I. , et al. Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections. Liver Int 2012; 32 (04) 603-611
    CrossrefPubMedGoogle Scholar
  • 16 Kalambokis GN, Oikonomou A, Christou L. , et al. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol 2016; 65 (05) 921-928
    CrossrefPubMedGoogle Scholar
  • 17 Di Martino V, Weil D, Cervoni JP, Thevenot T. New prognostic markers in liver cirrhosis. World J Hepatol 2015; 7 (09) 1244-1250
    CrossrefPubMedGoogle Scholar
  • 18 Raparelli V, Basili S, Carnevale R. , et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology 2017; 65 (02) 571-581
    CrossrefPubMedGoogle Scholar
  • 19 Moreau R, Jalan R, Gines P. , et al; CANONIC Study Investigators of the EASL–CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144 (07) 1426-1437
    CrossrefPubMedGoogle Scholar
  • 20 Papp M, Tornai T, Vitalis Z. , et al. Presepsin teardown - pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis. World J Gastroenterol 2016; 22 (41) 9172-9185
    CrossrefPubMedGoogle Scholar
  • 21 Tornai T, Vitalis Z, Sipeki N. , et al. Macrophage activation marker, soluble CD163, is an independent predictor of short-term mortality in patients with cirrhosis and bacterial infection. Liver Int 2016; 36 (11) 1628-1638
    CrossrefPubMedGoogle Scholar
  • 22 Foldi I, Tornai T, Tornai D. , et al. Lectin-complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections. Liver Int 2017; 37 (07) 1023-1031
    CrossrefPubMedGoogle Scholar
  • 23 Ikeda H, Tateishi R, Enooku K. , et al. Prediction of hepatocellular carcinoma development by plasma ADAMTS13 in chronic hepatitis B and C. Cancer Epidemiol Biomarkers Prev 2011; 20 (10) 2204-2211
    CrossrefPubMedGoogle Scholar
  • 24 Liu Y, Wang X, Li S. , et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics 2014; 106: 99-112
    CrossrefPubMedGoogle Scholar
  • 25 Cejka J. Enzyme immunoassay for factor VIII-related antigen. Clin Chem 1982; 28 (06) 1356-1358
    PubMedGoogle Scholar
  • 26 Mendelboum Raviv S, Szekeres-Csiki K, Jenei A. , et al. Coating conditions matter to collagen matrix formation regarding von Willebrand factor and platelet binding. Thromb Res 2012; 129 (04) e29-e35
    CrossrefPubMedGoogle Scholar
  • 27 Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129 (01) 93-100
    CrossrefPubMedGoogle Scholar
  • 28 Udvardy ML, Szekeres-Csiki K, Hársfalvi J. Novel evaluation method for densitometric curves of von Willebrand factor multimers and a new parameter (M(MW)) to describe the degree of multimersation. Thromb Haemost 2009; 102 (02) 412-417
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 29 Stockschlaeder M, Schneppenheim R, Budde U. Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 2014; 25 (03) 206-216
    CrossrefPubMedGoogle Scholar
  • 30 Pereboom ITA, Adelmeijer J, van Leeuwen Y, Hendriks HG, Porte RJ, Lisman T. No evidence for systemic platelet activation during or after orthotopic liver transplantation. Liver Transpl 2009; 15 (08) 956-962
    CrossrefPubMedGoogle Scholar
  • 31 Shenkman B, Savion N, Dardik R, Tamarin I, Varon D. Testing of platelet deposition on polystyrene surface under flow conditions by the cone and plate(let) analyzer: role of platelet activation, fibrinogen and von Willebrand factor. Thromb Res 2000; 99 (04) 353-361
    CrossrefPubMedGoogle Scholar
  • 32 Vanícková M, Suttnar J, Dyr JE. The adhesion of blood platelets on fibrinogen surface: comparison of two biochemical microplate assays. Platelets 2006; 17 (07) 470-476
    CrossrefPubMedGoogle Scholar
  • 33 Tornai I, Hársfalvi J, Boda Z, Udvardy M, Pfliegler G, Rak K. Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals. Haemostasis 1993; 23 (01) 58-64
    PubMedGoogle Scholar
  • 34 Ferro D, Quintarelli C, Lattuada A. , et al. High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia. Hepatology 1996; 23 (06) 1377-1383
    CrossrefPubMedGoogle Scholar
  • 35 Uemura M, Fujimura Y, Matsumoto M. , et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost 2008; 99 (06) 1019-1029
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 36 Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013; 58 (02) 752-761
    CrossrefPubMedGoogle Scholar
  • 37 Pereboom IT, Adelmeijer J, van Leeuwen Y, Hendriks HG, Porte RJ, Lisman T. Development of a severe von Willebrand factor/ADAMTS13 dysbalance during orthotopic liver transplantation. Am J Transplant 2009; 9 (05) 1189-1196
    CrossrefPubMedGoogle Scholar
  • 38 Favaloro EJ, Bonar R, Chapman K, Meiring M, Funk Adcock D. Differential sensitivity of von Willebrand factor (VWF) ‘activity’ assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen-binding and mAb-based assays. J Thromb Haemost 2012; 10 (06) 1043-1054
    CrossrefPubMedGoogle Scholar
  • 39 Fisher C, Patel VC, Stoy SH. , et al. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure. J Crit Care 2018; 43: 54-60
    CrossrefPubMedGoogle Scholar
  • 40 Federici AB, Berkowitz SD, Lattuada A, Mannucci PM. Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. Blood 1993; 81 (03) 720-725
    CrossrefPubMedGoogle Scholar
  • 41 Lancellotti S, De Filippis V, Pozzi N. , et al. Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS-13. J Thromb Haemost 2011; 9 (08) 1620-1627
    CrossrefPubMedGoogle Scholar
  • 42 Carnevale R, Raparelli V, Nocella C. , et al. Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. J Hepatol 2017; 67 (05) 950-956
    CrossrefPubMedGoogle Scholar
  • 43 Villa E, Cammà C, Marietta M. , et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143 (05) 1253-1260
    CrossrefPubMedGoogle Scholar
  • 44 Reuken PA, Kussmann A, Kiehntopf M. , et al. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int 2015; 35 (01) 37-45
    CrossrefPubMedGoogle Scholar
  • 45 Kleinegris MC, Bos MH, Roest M. , et al. Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity. J Thromb Haemost 2014; 12 (10) 1647-1657
    CrossrefPubMedGoogle Scholar
  • 46 Cao WJ, Niiya M, Zheng XW, Shang DZ, Zheng XL. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J Thromb Haemost 2008; 6 (07) 1233-1235
    CrossrefPubMedGoogle Scholar
  • 47 Furlan M, Robles R, Morselli B, Sandoz P, Lämmle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81 (01) 8-13
    Artikel in Thieme ConnectPubMedGoogle Scholar